Government Grants
Business Grants
Home Owner Programs
Federal Programs
About Us
Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) Biostatistics Research Center (BRC) (Collaborative U01 Clinical Trial Required)
The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to continue follow-up of the Diabetes Prevention Program Outcomes Study (DPPOS) cohort through a collaborative cooperative agreement.
The Diabetes Prevention Program (DPP) was a multi-center controlled clinical trial
examining the efficacy of treatments to prevent or delay the development of type 2 diabetes in a population at high risk.
The DPP demonstrated that either weight loss through lifestyle change or the drug metformin could reduce the development of type 2 diabetes by 58% and 31%, respectively, compared with placebo.
Following the end of DPP, the DPP cohort was enrolled in the DPPOS to determine the long-term effects of the DPP interventions on further diabetes development and microvascular complications.
The current funding period is focused on examining the effectiveness of early metformin treatment on the development of cancer and cardiovascular disease.
The DPPOS study population has aged, and there is an opportunity to study the heterogeneity in chronic disease development and progression in this well-characterized, diverse study population.
The primary purpose of this FOA is to support the DPPOS BRC to maintain follow-up the DPPOS cohort to continue to explore contributors to the development of multiple chronic conditions, including, but not limited to, cognitive impairment, cancer, and diabetes vascular complications, and to evaluate whether the DPP interventions have any preventive effect on the development of these chronic conditions.
RFA-DK-20-501 will support continuation of the DPPOS Clinical Centers.
The Diabetes Prevention Program (DPP) was a multi-center controlled clinical trial
examining the efficacy of treatments to prevent or delay the development of type 2 diabetes in a population at high risk.
The DPP demonstrated that either weight loss through lifestyle change or the drug metformin could reduce the development of type 2 diabetes by 58% and 31%, respectively, compared with placebo.
Following the end of DPP, the DPP cohort was enrolled in the DPPOS to determine the long-term effects of the DPP interventions on further diabetes development and microvascular complications.
The current funding period is focused on examining the effectiveness of early metformin treatment on the development of cancer and cardiovascular disease.
The DPPOS study population has aged, and there is an opportunity to study the heterogeneity in chronic disease development and progression in this well-characterized, diverse study population.
The primary purpose of this FOA is to support the DPPOS BRC to maintain follow-up the DPPOS cohort to continue to explore contributors to the development of multiple chronic conditions, including, but not limited to, cognitive impairment, cancer, and diabetes vascular complications, and to evaluate whether the DPP interventions have any preventive effect on the development of these chronic conditions.
RFA-DK-20-501 will support continuation of the DPPOS Clinical Centers.
Related Programs
Department of Health and Human Services
Cancer Cause and Prevention Research
Department of Health and Human ServicesDiabetes, Digestive, and Kidney Diseases Extramural Research
Department of Health and Human ServicesDepartment of Health and Human Services
Agency: Department of Health and Human Services
Office: National Institutes of Health
Estimated Funding: $1,200,000
Office: National Institutes of Health
Estimated Funding: $1,200,000
Who's Eligible
Relevant Nonprofit Program Categories
Obtain Full Opportunity Text:
http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-502.html
Additional Information of Eligibility:
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U. S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
See funding announcement for full eligibility information.
Full Opportunity Web Address:
http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-502.html
Contact:
Agency Email Description:
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Agency Email:
Date Posted:
2020-01-23
Application Due Date:
Archive Date:
2020-05-28
Social Entrepreneurship
Spotlight
Building a Million Dollar Company Where Everyone Counts
Ganesh Natarajan is the Founder and Chairman of 5FWorld, a new platform for funding and developing start-ups, social enterprises and the skills eco-system in India. In the past two decades, he has built two of India’s high-growth software services companies – Aptech and Zensar – almost from scratch to global success.
Learn How to Identify and Avoid Grant Scams
